Olanzapine treatment for patients with schizophrenia and substance abuse

Littrell, Kimberly H.; Petty, Richard G.; Hilligoss, Nicole M.; Peabody, Carol D.; Johnson, Craig

doi:10.1016/s0740-5472(01)00205-7

Cited by 81 publications

(47 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One open-label study suggested that it may help patients with schizophrenia to reduce use of cocaine and alcohol [29]. However, a naturalistic prospective study of outpatients reported that it was not more effective than conventional agents [30].…”

Section: Atypical Antipsychoticsmentioning

confidence: 99%

Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism?

Roth¹,

Brunette²,

Green

2005

Curr Psychiatry Rep

View full text Add to dashboard Cite

Substance use disorders (SUDs) are highly prevalent and are associated with poor outcomes among individuals with schizophrenia. Integrating treatments for both disorders improves outcomes. Numerous individual pharmacologic and psychosocial treatments have shown effectiveness at reducing substance use in individuals with a primary diagnosis of schizophrenia and co-occurring substance use disorders. Of these treatments, medications such as certain atypical antipsychotics and naltrexone, and psychosocial treatments such as contingency management, seem to be particularly promising. The development and evaluation of psychopharmacologic and psychosocial treatments for SUDs in schizophrenia would benefit from a better understanding of the neurobiological mechanisms underlying the effectiveness of such treatments. Several theories have been put forth to explain the heightened risk for SUDs in schizophrenia. Of these, brain reward circuitry dysfunction, hypothesized to be etiologically important in SUDs, may be an especially salient target for treatments aimed at the reduction of substance use in patients with schizophrenia. We review current pharmacologic and psychosocial treatments for SUDs in schizophrenia, and theoretical mechanisms underlying the increased risk for SUDs in this population. We propose that effective treatments may in part work through the modulation of brain reward circuitry dysfunction.

show abstract

Section: Atypical Antipsychoticsmentioning

confidence: 99%

Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism?

Roth¹,

Brunette²,

Green

2005

Curr Psychiatry Rep

View full text Add to dashboard Cite

show abstract

“…Kokain bağımlısı şizofreni tanılı hastalarda risperidon kullanımının relaps ve madde alma isteğinde azalmaya yol açtığını bildiren çalışmalar mevcuttur. [78] Yapı-lan bir çalışma ve iki olgu sunumu sonucuna göre, olanzapin kullanımı şizof-reni tanılı bireylerde kokain kullanma isteğini azaltıyor gibi görünüyorsa da, [79][80][81] başka bir çalışmada diğer atipik ajanlara göre üstünlüğü bulunmamıştır. [82] Parsiyel dopamin agonisti olan aripiprazol kullanan 10 hasta ile yapılan çalışma sonucunda kokain kullanım bozukluğu eş tanısı olan şizofreni tanılı hastalarda kokain kullanımını azalttığı bildirilmiştir.…”

Section: Tedavi Psikoterapiunclassified

Substance Use Disorder Comorbidity in Schizophrenia

Aras¹

2013

Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychia

View full text Add to dashboard Cite

ÖZETŞizofreni tanısı alan hastalarda alkol ve madde kullanımı yaygındır. Şizofreni-de alkol madde kullanım bozuklukları sıklığı yüksek olmasına rağmen yapılan tüm çalışmalarda madde kullanım ektanısının dışlanması bu alandaki verilerin çok kısıtlı olmasına yol açmıştır. Yüksek eştanılılığın açıklanmasında pek çok teori öne atılmıştır. Tipik antipsikotik ilaçların şizofreni tanılı hastalarda alkol ve madde kullanımına etkileri sınırlıdır. Atipik antipsikotik ilaçların özellikle klozapin kullanımının etkinliği gösterilmiştir. Literatüre baktığımızda, alkol kötüye kullanımı tedavisinde pek çok yeni ajan ortaya çıkmışsa da, sadece bir tanesinin (naltrekson) şizofreni tanılı hastalarda kullanımına dair çalışmalar mevcuttur. Bu hasta populasyonunda, farmakolojik yaklaşımların tek başına en uygun fayda getireceğini düşünmek doğru bir yaklaşım olmaz. Psikoterapinin de içerisinde bulunduğu, iyi koordine edilmiş bir tedavi planı mutlak hedef olmalıdır. Anahtar Sözcükler: Şizofreni, alkol-madde kullanım bozukluğu, eştanılılık. ABSTRACTUse of alcohol and other substances are commonly observed among patients with a diagnosis of schizophrenia. Despite this common comorbidity, there have been very few studies which do not take alcohol/substance use as an exclusion criterion. Thus we have very limited data on this specific area. A number of theories have been developed to explain these high comorbidity rates. Typical antipsychotic medications decreases alcohol or substance use in general, but this is valid only for a limited extend in patients with schizophrenia. On the other hand atypical antipsychotics, particularly clozapine plays an active role in that respect. Recently, we can see lots of new adjunctive medications formulated for the treatment of alcoholism, but only one of them (naltrexone) has thus far been carefully studied and tested in relation with these ©2013, Psikiyatride Güncel Yaklaşımlar eISSN:1309-0674 pISSN:1309-0658

show abstract

“…In a 12-month prospective, open-label trial of olanzapine [62] performed in 30 patients meeting DSM-IV criteria for schizophrenia or schizoaffective disorder and comorbid alcohol or cocaine dependence, 70% of the patients achieved early full remission and the remaining 30% early partial remission at the end of the study period, with 100% showing sustained abstinence from cocaine use. Significant improvements were noted in psychopathology, levels of hope, and reductions in antipsychotic-related side effects.…”

Section: Olanzapinementioning

confidence: 99%

Antipsychotic Drug Treatment of Schizophrenic Patients with Substance Abuse Disorders

San

Arranz²,

Martínez-Raga³

2007

Eur Addict Res

View full text Add to dashboard Cite

Background/Aim: In recent years, there has been a growing interest in developing adequate treatments for patients with a diagnosis of schizophrenia and a comorbid substance use disorder (SUD). In the present paper we aim to critically review published reports on the use of conventional and second-generation antipsychotics in the treatment of patients with schizophrenia and comorbid SUD, to provide clinicians with a clearer view of the pharmacological treatment of this highly prevalent dual diagnosis based upon the evidence arising from the scientific literature. Methods: A search of the relevant literature from Medline, PsycLIT and EMBASE databases, included in the Science Citation Index, and available up to November 2006 was conducted using the terms: ‘schizophrenia’, ‘substance use disorder’ and ‘antipsychotics’. Results: While research on the use of conventional antipsychotics has remained limited, the majority of studies suggest the effectiveness of second-generation antipsychotics, particularly clozapine, for patients with schizophrenia and a comorbid substance use disorder. Conclusion: In the absence of randomized controlled trials that could provide more reliable information, clinical decisions may need to rely on indirect data provided by the increasing number of case reports, open trials and retrospective studies showing a decrease in cigarette smoking, alcohol, cocaine or cannabis use and an improvement of overall psychiatric symptoms.

show abstract

Olanzapine treatment for patients with schizophrenia and substance abuse

Cited by 81 publications

References 32 publications

Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism?

Treatment of substance use disorders in schizophrenia: A unifying neurobiological mechanism?

Substance Use Disorder Comorbidity in Schizophrenia

Antipsychotic Drug Treatment of Schizophrenic Patients with Substance Abuse Disorders

Contact Info

Product

Resources

About